Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Menarini Stemline at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Menarini Stemline exhibits at Booth 229 at ASH 2026 in New Orleans. Menarini Stemline supports a symposium on blastic plasmacytoid dendritic cell neoplasm. It pairs updated diagnostic pathways with current and emerging therapies aimed at CD123.

OrganizationASH 2026 Attendance
Menarini Stemline
New York, NY
Biotech
Menarini Group subsidiary developing and selling oncology drugs, including a CD123-directed therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Booth
Exhibiting at Booth 229
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies
Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Menarini Stemline

Tell us what you sell and we’ll find the people at Menarini Stemline most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction